Tonix Pharmaceuticals Holding Corp. (TNXP) Bundle
A Brief History of Tonix Pharmaceuticals Holding Corp. (TNXP)
Foundation and Early Development
Tonix Pharmaceuticals Holding Corp. was founded in 2012 and is based in New York, NY. The company focuses on developing innovative treatments for CNS disorders, specifically post-traumatic stress disorder (PTSD), fibromyalgia, and other pain conditions.
Initial Public Offering (IPO)
Tonix went public on April 29, 2014, with its initial public offering (IPO) priced at $5.00 per share. The company raised $10 million through the offering.
Key Clinical Trials and Developments
In 2016, Tonix announced its Phase 2 clinical trial results for TNX-102 SL, a sublingual formulation of cyclobenzaprine for the treatment of fibromyalgia. The trial demonstrated significant improvement in daily pain levels.
By 2020, the company transitioned to a Phase 3 clinical trial, known as the RELIEF study, for TNX-102 SL, confirming the efficacy and safety of the drug in fibromyalgia patients.
Partnerships and Collaborations
In 2018, Tonix entered into a collaboration agreement with a subsidiary of the U.S. Army to conduct clinical trials assessing TNX-102 SL for PTSD. This partnership aimed to evaluate the drug's potential in military populations.
Financial Performance
| Year | Revenue (in millions) | Net Loss (in millions) | Market Capitalization (as of October 2023, in millions) |
|---|---|---|---|
| 2020 | 0.00 | (15.11) | 62.30 |
| 2021 | 0.00 | (17.63) | 45.50 |
| 2022 | 0.00 | (19.79) | 56.70 |
| 2023 | 0.00 | (18.25) | 34.10 |
Recent Developments and Future Prospects
In early 2023, Tonix began a Phase 3 trial for TNX-102 SL for the treatment of PTSD, responding to favorable results from earlier trials. As of October 2023, the company is actively seeking to expand its pipeline, with additional programs focused on psychiatric and pain disorders.
Stock Performance
As of October 2023, the stock price of Tonix Pharmaceuticals (TNXP) fluctuated around $0.78 per share, reflecting a challenging market environment for biotech companies.
Conclusion
Despite the hurdles, Tonix Pharmaceuticals continues to push forward, focusing on innovative solutions to unmet medical needs within the CNS space.
A Who Owns Tonix Pharmaceuticals Holding Corp. (TNXP)
Shareholder Composition
As of the latest available data, the ownership structure of Tonix Pharmaceuticals Holding Corp. (TNXP) is divided among institutional investors, retail investors, and insiders. The following table summarizes the major shareholders and their respective ownership percentages:
| Shareholder Type | Shareholder Name | Ownership Percentage (%) |
|---|---|---|
| Institutional Investor | BlackRock, Inc. | 8.15 |
| Institutional Investor | The Vanguard Group, Inc. | 6.27 |
| Institutional Investor | Nasdaq, Inc. | 5.40 |
| Insiders | Dr. Seth Lederman | 4.50 |
| Retail Investor | Public Float | 75.68 |
Recent Stock Performance
The stock price of TNXP has seen varied performance in recent months. As of the end of the last trading session, the stock closed at $0.89, with a market capitalization of approximately $83 million. The following table details the stock performance metrics:
| Metric | Value |
|---|---|
| Current Stock Price (USD) | 0.89 |
| Market Capitalization (USD) | 83 million |
| 52-Week Range (USD) | 0.70 - 1.50 |
| Average Volume (Shares) | 1.2 million |
| PE Ratio | N/A |
Recent Financing Activities
Tonix Pharmaceuticals has engaged in several financing rounds to support its operational activities. The following table outlines the amounts raised in recent financings:
| Date | Financing Type | Amount Raised (USD) |
|---|---|---|
| March 2023 | Public Offering | 20 million |
| June 2023 | Private Placement | 10 million |
| September 2023 | Equity Financing | 5 million |
Insider Transactions
Insider transactions provide insight into the confidence of the management regarding the company's future. The table below summarizes recent insider transactions:
| Date | Insider Name | Transaction Type | Shares Bought/Sold |
|---|---|---|---|
| April 2023 | Dr. Seth Lederman | Buy | 100,000 |
| June 2023 | Dr. Jacqueline A. Sideris | Sell | 50,000 |
| August 2023 | Dr. Seth Lederman | Buy | 75,000 |
Future Ownership Projections
Analysts forecast that institutional ownership in TNXP may increase due to recent initiatives to enhance shareholder value. Current estimates suggest a potential rise in institutional holdings to approximately 15% over the next 12 months.
Tonix Pharmaceuticals Holding Corp. (TNXP) Mission Statement
Company Overview
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders and pain. The company aims to advance innovative therapies to improve the quality of life for patients.
Mission Statement
Tonix Pharmaceuticals’ mission is to develop and commercialize innovative therapies that address significant unmet medical needs in the fields of central nervous system disorders, pain, and infectious diseases. The company emphasizes the importance of scientific rigor, patient-centricity, and ethical practices in its approach to drug development.
Key Components of the Mission Statement
- Innovative Therapies: Commitment to cutting-edge research and development.
- Patient-Centric Approach: Focus on enhancing patient outcomes and experiences.
- Unmet Medical Needs: Targeting areas with limited treatment options.
- Collaborative Efforts: Engaging with healthcare professionals and stakeholders.
Strategic Goals
The strategic goals of Tonix Pharmaceuticals align with its mission and include:
- Advancing the clinical development of lead product candidates.
- Enhancing operational efficiencies to reduce development timelines.
- Expanding partnerships with research institutions and other pharmaceutical companies.
- Securing funding to support ongoing clinical trials and research initiatives.
Financial Overview
As of the latest financial report, Tonix Pharmaceuticals reported total revenue of $1.2 million for the year ended December 31, 2022. The company’s net loss for the same period was $23.4 million.
Research and Development Investment
Tonix Pharmaceuticals places a strong emphasis on research and development. For the fiscal year 2022, the company invested approximately $15 million in R&D activities.
Current Product Candidates
| Product Candidate | Indication | Development Stage | Estimated Completion Date |
|---|---|---|---|
| TNX-102 SL | Fibromyalgia | Phase 3 | Q4 2023 |
| TNX-601 CR | PTSD | Phase 2 | Q2 2024 |
| TNX-1900 | Chronic Pain | Preclinical | 2025 |
Recent Developments
In 2023, Tonix Pharmaceuticals announced a successful completion of its Phase 2 clinical trial for TNX-102 SL, demonstrating significant improvements in patient-reported outcomes.
Market Position
As of the latest market data, Tonix Pharmaceuticals had a market capitalization of approximately $40 million, reflecting investor interest in the company's innovative approach to addressing complex medical conditions.
Future Outlook
Tonix Pharmaceuticals aims to maximize shareholder value by advancing its pipeline of therapeutic candidates and seeking strategic partnerships and collaborations. The company continues to pursue opportunities for funding and investment to fuel its growth and innovation.
How Tonix Pharmaceuticals Holding Corp. (TNXP) Works
Company Overview
Company Overview
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders and pain conditions. The company is headquartered in New York City and operates with the goal of addressing significant unmet medical needs. As of Q3 2023, Tonix’s market capitalization was approximately $36.5 million.
Key Products and Pipeline
Tonix has a diversified pipeline with several key products:
- TX-001HR: A treatment for post-traumatic stress disorder (PTSD) in Phase 3 clinical trials.
- TX-004HR: A potential treatment for opioid use disorder, currently in Phase 2 clinical trials.
- TX-003HR: A novel formulation for chronic pain management, in preclinical development.
Financial Performance
As of the end of Q3 2023, Tonix Pharmaceuticals reported the following financial metrics:
| Metric | Value |
|---|---|
| Revenue | $1.2 million |
| Net Loss | $15.4 million |
| Cash and Cash Equivalents | $10.7 million |
| Research and Development Expenses | $9.8 million |
| General and Administrative Expenses | $5.6 million |
Market Strategy
Tonix employs a multifaceted market strategy, focusing on:
- Partnering with academic institutions for research collaborations.
- Engaging with the FDA for expedited development pathways.
- Leveraging investor relations to secure funding for clinical trials.
Recent Developments
In September 2023, Tonix announced a strategic partnership with a major academic institution, enhancing its research capabilities. Additionally, the company raised $5 million in a public offering to bolster its clinical programs and support ongoing research.
Regulatory Environment
Tonix operates within a highly regulated environment, complying with FDA guidelines. As of Q3 2023, the company is preparing submissions for Investigational New Drug (IND) applications for TX-004HR and TX-003HR.
Competitive Landscape
The competitive landscape for Tonix Pharmaceuticals includes several key players in the CNS and pain management sectors:
| Company | Focus Area | Market Cap (as of Q3 2023) |
|---|---|---|
| Neurocrine Biosciences | CNS Disorders | $5.1 billion |
| Acadia Pharmaceuticals | Psychiatric Disorders | $2.5 billion |
| Purdue Pharma | Pain Management | N/A (bankruptcy proceedings) |
| Emerald Health Therapeutics | Cannabis-based therapeutics | $76.3 million |
Investor Relations
Tonix's investor relations strategy includes regular updates through earnings calls and investor presentations. In Q3 2023, the company reported a shareholder base of approximately 8,000 investors. The stock price fluctuated between $0.45 and $0.75 during the quarter, reflecting market interest and volatility.
Conclusion
Tonix Pharmaceuticals continues to develop innovative treatments, leveraging their pipeline and strategic partnerships to enhance their market position in the biopharmaceutical industry.
How Tonix Pharmaceuticals Holding Corp. (TNXP) Makes Money
Product Development and Commercialization
Tonix Pharmaceuticals focuses on developing innovative treatments primarily in the fields of central nervous system (CNS) disorders and pain management. As of 2023, the company's leading product candidates include:
- TNX-102 SL - A sublingual formulation of cyclobenzaprine, targeting fibromyalgia.
- TNX-1900 - A formulation aimed at treating migraine headaches.
- TNX-601 - A nasal spray intended to address post-traumatic stress disorder (PTSD).
Revenue Streams
Tonix generates its revenue through several avenues:
- License agreements with other pharmaceutical firms.
- Government grants for research and development.
- Commercial sales from FDA-approved products.
Financial Overview
The following table presents relevant financial data for Tonix Pharmaceuticals as of the end of Q2 2023:
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue | $1.2 million |
| R&D Expenses | $9.8 million |
| Net Income (Loss) | $(8.5 million) |
| Cash and Cash Equivalents | $21.7 million |
| Total Assets | $32.3 million |
| Total Liabilities | $15.0 million |
Partnerships and Collaborations
Tonix has entered into strategic partnerships to enhance its pipeline and financial standing:
- Collaboration with the U.S. Department of Defense for research on PTSD treatments.
- Licensing agreements with other biotech firms to co-develop products.
Market Accessibility
The company aims to tap into the growing biotechnology market, which has shown substantial growth potential:
- Global CNS drugs market is projected to reach approximately $170 billion by 2027.
- The pain management market is expected to exceed $80 billion by 2025.
Future Prospects
Tonix is actively pursuing clinical trials to move its products towards commercialization:
- Phase 3 trial for TNX-102 SL is anticipated to commence in late 2023.
- Plans to submit regulatory filings for TNX-1900 in 2024.
Stock Performance
As of October 2023, the stock performance of TNXP is as follows:
| Stock Metric | Value |
|---|---|
| Current Price | $0.65 |
| Market Capitalization | $56 million |
| 52-Week High | $1.25 |
| 52-Week Low | $0.50 |
| Average Daily Volume | 500,000 shares |
Tonix Pharmaceuticals Holding Corp. (TNXP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support